From clinical fail to raising cash? Virios goes for public offering as shares reach all-time low

Paul Schloesser

Associate Editor

After a massive Phase IIb fail, antiviral biotech Virios is scrambling to bring in extra capital — all while the biotech’s shares have now reached their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

From clinical fail to raising cash? Virios goes for public offering as shares reach all-time low

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

European drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug

Gilead will close Philadelphia, Seattle offices as part of job reductions

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

From clin­i­cal fail to rais­ing cash? Virios goes for pub­lic of­fer­ing as shares reach all-time low

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

From clinical fail to raising cash? Virios goes for public offering as shares reach all-time low

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

European drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug

Gilead will close Philadelphia, Seattle offices as part of job reductions

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?